These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 1698546

  • 1. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P, Beardmore C, Liu LF.
    Cancer Res; 1990 Nov 01; 50(21):6919-24. PubMed ID: 1698546
    [Abstract] [Full Text] [Related]

  • 2. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Kaufmann SH.
    Cancer Res; 1991 Feb 15; 51(4):1129-36. PubMed ID: 1705167
    [Abstract] [Full Text] [Related]

  • 3. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C, Covey JM, Kerrigan D, Pommier Y.
    Cancer Res; 1989 Nov 15; 49(22):6365-8. PubMed ID: 2553254
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of protein synthesis reduces the cytotoxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line.
    Schneider E, Lawson PA, Ralph RK.
    Biochem Pharmacol; 1989 Jan 15; 38(2):263-9. PubMed ID: 2464346
    [Abstract] [Full Text] [Related]

  • 5. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S, Riou G.
    Biochem Pharmacol; 1994 Aug 30; 48(5):975-84. PubMed ID: 8093110
    [Abstract] [Full Text] [Related]

  • 6. A novel use for the comet assay: detection of topoisomerase II inhibitors.
    Salti GI, Das Gupta TK, Constantinou AI.
    Anticancer Res; 2000 Aug 30; 20(5A):3189-93. PubMed ID: 11062742
    [Abstract] [Full Text] [Related]

  • 7. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M, Sehested M, Jensen PB.
    Mol Pharmacol; 1999 Mar 30; 55(3):424-31. PubMed ID: 10051525
    [Abstract] [Full Text] [Related]

  • 8. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4067-77. PubMed ID: 2825713
    [Abstract] [Full Text] [Related]

  • 9. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC, Ashorn CL, Chan D, Zwelling LA.
    Cancer Res; 1989 Apr 15; 49(8):2052-8. PubMed ID: 2539251
    [Abstract] [Full Text] [Related]

  • 10. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
    Del Bino G, Skierski JS, Darzynkiewicz Z.
    Exp Cell Res; 1991 Aug 15; 195(2):485-91. PubMed ID: 1649059
    [Abstract] [Full Text] [Related]

  • 11. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 15; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 12. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine.
    López-Baena M, Mateos S, Piñero J, Trinidad Ortiz, Cortés F.
    Mutat Res; 1998 Oct 12; 421(1):109-16. PubMed ID: 9748527
    [Abstract] [Full Text] [Related]

  • 13. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 14. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.
    Hsiang YH, Lihou MG, Liu LF.
    Cancer Res; 1989 Sep 15; 49(18):5077-82. PubMed ID: 2548710
    [Abstract] [Full Text] [Related]

  • 15. Importance of replication fork progression for the induction of chromosome damage and SCE by inhibitors of DNA topoisomerases.
    Cortés F, Piñero J, Ortiz T.
    Mutat Res; 1993 Oct 15; 303(2):71-6. PubMed ID: 7692280
    [Abstract] [Full Text] [Related]

  • 16. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
    Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Whang-Peng J.
    Cancer Res; 1988 Feb 01; 48(3):512-6. PubMed ID: 2825977
    [Abstract] [Full Text] [Related]

  • 17. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH, Castora FJ.
    Arch Biochem Biophys; 1995 Dec 20; 324(2):293-9. PubMed ID: 8554321
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G, Darzynkiewicz Z.
    Cancer Res; 1991 Feb 15; 51(4):1165-9. PubMed ID: 1997159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.